Calithera Biosciences, Inc. focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.The company is developing an oral arginase inhibitor that has completed Phase 1b clinical trial for cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73.
